Pharmaceutical Commerce

AUGUST 8, 2024

Will the looming changes address the concerns of the patient assistance community?

Patients 98

Patients 98

Eversana Intouch

NOVEMBER 18, 2024

2: the direct-to-patient model ) in a paradigm that’s interconnected (No. In this report, 15 of our experts examine the current impact of each of these three forces, predict how you’ll see their effects in 2025 and give recommendations for how to make these market forces work for you. Technology (No.

Marketing 59

Marketing Pharma Competition Patients 59

Pharma Marketing Network

DECEMBER 4, 2024

As we approach 2025, emerging trends are reshaping how the industry engages with patients and healthcare providers. With advancements in technology, increasing competition, and changing patient expectations, pharma marketers need to stay ahead of the curve. Patient-Centric Marketing Patients want to feel heard.

Marketing 52

Marketing Pharma Media Education 52

MedCity News

JANUARY 16, 2023

A budget estimate attached to proposed legislation in Montana raises questions about whether the state’s cash-strapped communities will have the capacity to care for patients with Alzheimer’s disease, other types of dementia or traumatic brain injuries by July 2025, when involuntary commitments would cease under the plan.

Patients 129

Patients 129

European Pharmaceutical Review

DECEMBER 19, 2024

1 These concerns are held alongside the promise of this technology and its potential for improving efficiency, enhancing patient outcomes, and addressing critical challenges like staffing shortages. In 2025, organisations must focus on addressing data integrity challenges. Computers in Biology and Medicine. 2024; 177: 108632.

Pharmaceutical 52

Pharmaceutical Ethics Medicine Pharma 52

Pharma Marketing Network

NOVEMBER 1, 2024

The world of pharma marketing is changing rapidly, and 2025 will be no exception. So, what will be the top challenges in 2025, and how can pharma marketers tackle them? This shift includes everything from leveraging social media to engaging patients through apps and personalized email campaigns.

Marketing 52

Marketing Pharma Ethics Healthcare Provider 52

MedCity News

JULY 24, 2023

Investment is expected to continue trending upward, with estimates suggesting that global spending on rare disease therapies will reach $260 billion by the end of 2025. In 2020, 46.9% of all novel drugs approved by the FDA were for rare diseases, as compared to 23.5%

Patients 97

Patients FDA Biopharma 97

Pharmaceutical Commerce

NOVEMBER 4, 2024

With a 26% decline in prescription drug plans from 2024 to 2025, navigating potential gaps and accessing care remains vital for low income patients.

Prescription 52

Prescription Patients 52

pharmaphorum

OCTOBER 8, 2024

Shares in Scholar Rock have gone into overdrive after the biotech reported positive phase 3 results with apitegromab in patients with spinal muscular atrophy (SMA), setting up regulatory filings in early 2025.The The stock rocketed 362% after the announcement, taking Scholar Rock's market cap above $2.7

Sales 111

Sales Marketing Patients 111

Tribeca Knowledge

OCTOBER 1, 2024

M arket Access 2025, a new report from TRiBECA Knowledge, offers a fresh perspective on how the market access landscape for medicines continues to raise the bar for launch success and consistently better patient outcomes.

Marketing 52

Marketing Medicine Patients 52

MedCity News

MARCH 28, 2023

Aneesh Chopra, president and co-founder of CareJourney, predicted accelerated enrollment in value-based care models in 2024 and 2025.

Healthcare 113

Healthcare Healthcare Doctors Patients 113

World of DTC Marketing

JULY 17, 2022

Novo Nordisk more than doubled its sales targets for obesity drugs to $3.7bn by 2025. It has to persuade patients to sign up for some heinous side effects. When patients stop taking Wegovy, their appetite returns within weeks, and they pack on weight. Its share price has risen 26 percent in the past year.

Side effects 209

Side effects Doctors Insurance Prescription 209

Pharmaceutical Commerce

JUNE 2, 2023

The Medicare Part D cap in 2025 won’t solve patients’ need for financial assistance.

Patients 98

Patients 98

Pharma Marketing Network

OCTOBER 17, 2024

As we approach 2025, the ability of pharmaceutical companies to effectively craft and communicate their brand identity will play a pivotal role in determining their market success. Key Strategies for Pharma Marketing in 2025 As pharmaceutical companies look to 2025, embracing a patient-centric approach will be pivotal.

Healthcare 52

Healthcare Healthcare Marketing Pharma 52

European Pharmaceutical Review

FEBRUARY 28, 2024

The implementation of the EU’s Health Technology Assessment Regulation (HTAR) 1 will play a key role in shaping the patient access pathway for ATMPs such as cell and gene therapies. Currently, these therapies primarily target rare or ultra-rare diseases with small patient populations, which therefore limits clinical study sizes.

Patients 97

Patients Ethics Healthcare Healthcare 97

Contrarian Sales Techniques

OCTOBER 19, 2024

Malaysia’s Budget 2025 is out, on October 18th 2024, and it’s packed with changes that will touch nearly every aspect of your lives and mine, from salaries to taxes, and even our environment. Now, before you celebrate, this change kicks in February 2025, so we have to wait a bit. Boosting Wages (Finally!) What about you?

Medical sales 52

Medical sales Medical sales reps Government Ethics 52

PharmExec

DECEMBER 20, 2024

In this part of his Pharmaceutical Executive video interview, Peter Ax, CEO of UpScriptHealth, discusses the recent DEA extensions of telehealth for controlled substances and new treatment modalities or patient populations he anticipates will become more accessible through telehealth in 2025.

Patients 52

Patients Pharmaceutical 52

PM360

NOVEMBER 12, 2024

The 2025 Healthcare CNO Summit , an exclusive invitation-only event, is scheduled for February 3-4, 2025, at The Ritz-Carlton Dallas, Las Colinas. Quality Safety Controls: Mitigating challenges to ensure patient safety and quality care.

Healthcare 52

Healthcare Healthcare Safety Networking 52

Pharma Marketing Network

OCTOBER 17, 2024

As we approach 2025, the pharmaceutical industry is witnessing a seismic shift in marketing strategies, driven by technological advancements and evolving consumer expectations. As patients become more digitally savvy, pharma companies are investing in creating seamless digital experiences that cater to their needs and preferences.

Marketing 52

Marketing Healthcare Healthcare Pharma 52

Nixon Gwilt Law

JULY 12, 2024

The 2025 Medicare Physician Fee Schedule Proposed Rule (the “2025 Proposed Rule”) issued by the Centers for Medicare and Medicaid Services (or “CMS”) on July 10, 2024 contains a number of new policy proposals with significant implications for healthcare innovators.

Physicians 52

Physicians Management Food and Drug Administration Healthcare 52

Prognos Health

NOVEMBER 18, 2021

This in-person event brought healthcare leaders together to discuss emerging opportunities and challenges around the use of health data to improve patient outcomes. More data should uncover more info about the patient. This includes clinical sensors and devices providing patient-generated data. Data key for health equity.

Healthcare 52

Healthcare Healthcare Patients Healthcare Provider 52

Nixon Gwilt Law

NOVEMBER 8, 2024

CMS issued its 2025 Medicare Physician Fee Schedule (the “2025 MPFS” or “Final Rule”) on November 1, 2024. The Final 2025 MPFS contains some modifications and clarifications to several elements of the original proposal released in July 2024 (the “Proposed Rule”), which we discussed in this earlier post.

FDA 52

FDA Physicians Management Patients 52

European Pharmaceutical Review

AUGUST 1, 2022

The joint Big Data Steering Group of the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) has published a third workplan, setting actions to be delivered by 2025. According to EMA, the new plan will further enhance the efficient integration of data analysis into the regulatory evaluation of medicinal products.

Medicine 105

Medicine Networking Electronics Healthcare 105

European Pharmaceutical Review

JUNE 10, 2024

“Coupled with the lead-212 production capacity of our research unit in Plano, Texas – the Domestic Distribution & Purification Unit – this new industrial site [in Brownsburg] will enable us to serve North American patients requiring targeted lead-212 radiotherapy treatments,” Guillaume Dureau commented. .

Manufacturing 98

Manufacturing Distribution Pharmaceutical manufacturing Leads 98

pharmaphorum

SEPTEMBER 9, 2022

It also marks the first move by Kry beyond the primary care category, where it provides virtual GP consultation services to millions of patients across various European countries, into tools for the treatment and prevention of chronic diseases. billion in 2025. Novo Nordisk recently predicted its obesity sales could reach $3.7

Pharmacology 113

Pharmacology Patients Management Sales 113

European Pharmaceutical Review

NOVEMBER 21, 2023

According to GSK, thirty-five million patients with respiratory conditions globally relying on its metered dose inhaler. Dosing of first patients is planned in the first half of 2024. However, this accounts for nearly half of GSK’s carbon footprint, and contributes to the carbon footprint of global health systems.

Manufacturing 116

Manufacturing Patients Pharma Leads 116

Nixon Gwilt Law

JULY 23, 2024

In the recently released 2025 Medicare Physician Fee Schedule Proposed Rule (the “Proposed Rule”), the Centers for Medicare & Medicaid Services (CMS) created a new reimbursement pathway for “Digital Mental Health Treatment” (DMHT) devices and services. for conditions other than substance abuse disorder, insomnia, and depression)?

Physicians 52

Physicians FDA Safety Management 52

pharmaphorum

OCTOBER 6, 2022

Fresh with a new brand identity, the France-headquartered pharma group has pledged to grow its oncology sales from its current objective of €1 billion in 2025 to €3 billion in 2030, continuing a diversification of its business from its traditional focus on cardiovascular diseases. billion and $1.8 billion, respectively, five years later.

Sales 98

Sales Pharma Government Medicine 98

Nixon Gwilt Law

JULY 23, 2024

In the recently released 2025 Medicare Physician Fee Schedule Proposed Rule (the “Proposed Rule”), the Centers for Medicare & Medicaid Services (CMS) created a new reimbursement pathway for “Digital Mental Health Treatment” (DMHT) devices and services. for conditions other than substance abuse disorder, insomnia, and depression)?

Physicians 52

Physicians FDA Safety Management 52

pharmaphorum

DECEMBER 9, 2024

Our experts will delve into the evolving landscape of life sciences and patient care, driven by cutting-edge technology, data insights, and a renewed commitment to inclusive, patient-centred solutions.

Patients 40

Patients 40

European Pharmaceutical Review

FEBRUARY 1, 2023

The system includes a public, searchable database for healthcare professionals, patients, and other interested parties. The CTR foresees a three-year transition period, from 2022 to 2025. With CTIS, sponsors can now apply for authorisations in up to 30 EU/EEA countries at the same time and with the same documentation.

Ethics 104

Ethics Government Medicine Healthcare 104

European Pharmaceutical Review

FEBRUARY 2, 2024

So construction of the new radioligand therapy manufacturing site in France is a major step towards making these promising new treatments available to cancer patients with high unmet needs.

Manufacturing 98

Manufacturing Distribution Leads Pharmaceutical 98

European Pharmaceutical Review

FEBRUARY 27, 2024

The new facility, known as Amgen Ohio, “was designed with the latest innovation and technology to deliver safe, reliable medicines for ‘every patient, every time,'” stated Robert Bradway, Chairman and Chief Executive Officer at Amgen. It is the company ’s most advanced manufacturing facility to date.

Manufacturing 105

Manufacturing Food and Drug Administration Food Networking 105

European Pharmaceutical Review

OCTOBER 22, 2024

The UK is set to be the first country to introduce a new regulatory framework for innovative products manufactured at or close to the point of patient care, says the Medicines and Healthcare products Regulatory Agency (MHRA). The agency anticipated that the regulation could become law in Summer 2025.

Medicine 89

Medicine Manufacturing Safety Consulting 89

European Pharmaceutical Review

APRIL 1, 2024

The two-year data showed that ABBV-RGX-314 provided stable or improved visual acuity and retinal thickness in patients. Importance of the findings Based on these data, subject to regulatory approval, a one-time dose of the gene therapy could provide a novel therapy option for patients with wet AMD.

Consulting 98

Consulting Safety Patients Management 98

European Pharmaceutical Review

JUNE 13, 2024

Significant reductions of treated bleeding episodes in haemophilia A In the FRONTIER 2 trial, treatment once-weekly and once-monthly with Mim8 provided a 97 percent and 99 percent reduction in treated bleeds in patients with no prior prophylaxis treatment, respectively. This was compared to prior coagulation factor prophylaxis.

Safety 98

Safety Patients Pharmaceutical 98

Pharmaceutical Technology

MAY 19, 2023

The US Food and Drug Administration (FDA) has approved AbbVie’s Rinvoq (upadacitinib) for patients with Crohn’s disease who do not respond to TNF blockers, a common immune suppressant treatment for the condition. Data from two Phase III studies, U-EXCEED and U-EXCEL, involving 857 patients was used to support the approval.

Food and Drug Administration 105

Food and Drug Administration FDA Sales Food 105